The primary outcome of the study is to evaluate the efficacy of home-based tDCS combined with remote cognitive training on direct testing of executive function in survivors of ALL.
Researchers are seeking to compare the efficacy and safety of the combination of ibrutinib and venetoclax compared with ibrutinib and placebo in patients with mantle cell lymphoma.
Investigators seek to evaluate how the addition of inotuzumab ozogamicin to frontline chemotherapy affects patients with newly diagnosed B-cell ALL.
Nearly three-quarters of patients responded to treatment.
Survival rates were similar whether maintenance was given every 12 weeks or every 4 weeks.
Gemtuzumab ozogamicin improved event-free survival and disease-free survival.
The signature was prognostic for locoregional recurrence.
Rates of SARS-CoV-2 infection and COVID-19-related death were similar among patients receiving cytotoxic and non-cytotoxic therapy.
Endocrine therapy was associated with fewer adverse events.
Younger patients had a significant decrease in sleep time on days they received dexamethasone.
Please login or register first to view this content.
